margetuximab (MGAH 22) - MacroGenics
Margetuximab: Acceptance of regulatory submission for HER2 + metastatic breast cancer in Q1 2020 (Macrogenics) - Jan 17, 2020 - Corporate Presentation: PDUFA action date for HER2 + metastatic breast cancer in Q4 2020 
BLA • PDUFA date
http://ir.macrogenics.com/static-files/c73fd3d3-6a17-4f04-95d9-3d6c39eb7411
 
Jan 17, 2020
 
 
8b7a809e-9ced-462a-9eff-7951e6a6ac15.jpg